Article

Blood-brain barrier transport of cytokines: A mechanism for neuropathology

GRECC, Veterans Affairs Medical Center-St. Louis & Saint Louis University School of Medicine, Division of Geriatrics, Department of Internal Medicine, 915 North Grand Blvd., St. Louis, MO 63106, USA.
Current Pharmaceutical Design (Impact Factor: 3.29). 02/2005; 11(8):973-84. DOI: 10.2174/1381612053381684
Source: PubMed

ABSTRACT Cytokines circulating in the blood affect CNS function through a variety of pathways. One of these pathways is by being transported directly across the blood-brain barrier (BBB). Transport of blood-borne cytokines across the BBB is now known to be an operational pathway by which cytokines can directly affect CNS functions. Cytokine transport across the BBB, however, is a complex event. Not all cytokines are transported and, for those which are, transport rates differ among cytokines, among brain regions, with physiological circumstances, and with disease. Here we address some of the major principles and concepts relating to cytokine transport and BBB function which have emerged as important to neuroimmunology and neuropathology.

1 Follower
 · 
65 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) is the first and second most prevalent motor and neurodegenerative disease, respectively. The clinical symptoms of PD result from a loss of midbrain dopaminergic (DA) neurons. However, the molecular cause of DA neuron loss remains elusive. Mounting evidence implicates enhanced inflammatory response in the development and progression of PD pathology. This review examines current research connecting PD and inflammatory response. © 2015 by the Society for Experimental Biology and Medicine.
    Experimental Biology and Medicine 03/2015; DOI:10.1177/1535370215576313 · 2.23 Impact Factor
  • Neurologia i neurochirurgia polska 01/2011; 45(3):275-285. DOI:10.1016/S0028-3843(14)60080-3 · 0.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Associative learning processes are one of the major neuropsychological mechanisms steering the placebo response in different physiological systems and end organ functions. Learned placebo effects on immune functions are based on the bidirectional communication between the central nervous system (CNS) and the peripheral immune system. Based on this "hardware," experimental evidence in animals and humans showed that humoral and cellular immune functions can be affected by behavioral conditioning processes. We will first highlight and summarize data documenting the variety of experimental approaches conditioning protocols employed, affecting different immunological functions by associative learning. Taking a well-established paradigm employing a conditioned taste aversion model in rats with the immunosuppressive drug cyclosporine A (CsA) as an unconditioned stimulus (US) as an example, we will then summarize the efferent and afferent communication pathways as well as central processes activated during a learned immunosuppression. In addition, the potential clinical relevance of learned placebo effects on the outcome of immune-related diseases has been demonstrated in a number of different clinical conditions in rodents. More importantly, the learned immunosuppression is not restricted to experimental animals but can be also induced in humans. These data so far show that (i) behavioral conditioned immunosuppression is not limited to a single event but can be reproduced over time, (ii) immunosuppression cannot be induced by mere expectation, (iii) psychological and biological variables can be identified as predictors for this learned immunosuppression. Together with experimental approaches employing a placebo-controlled dose reduction these data provide a basis for new therapeutic approaches to the treatment of diseases where a suppression of immune functions is required via modulation of nervous system-immune system communication by learned placebo effects.
    Zeitschrift für Psychologie 01/2014; 222(3):148-153. DOI:10.1027/2151-2604/a000184 · 1.57 Impact Factor